IL15 and melanoma: A study in murine models of melanoma has also shown that while STING agonists can lead to regression of injected tumors, treatment of IL-15Rα−/− knockout mice with STING agonists had no effect on distant secondary tumors; hence, STING-mediated abscopal immunity required expression of IL-15 (47).